Investor Presentaiton

Department of Health Notes to the financial statements For the year ended on 30 June 2023 7 Financing This section sets out the material balances and disclosures associated with the financing and cashflows of the department. Notes 7.1 74 7.1.1 Cash and cash equivalents Lease liabilities Finance costs Commitments Cash and cash equivalents Reconciliation of cash 7.1 7.2 7.3 7.4 Cash and cash equivalents Restricted cash and cash equivalents Total cash and cash equivalents at end of period 2023 $'000 68,912 119,530 188,442 2022 $'000 128,508 123,619 252,127 For the purpose of the statement of cash flows, cash and cash equivalent (and restricted cash and cash equivalent) assets comprise cash on hand and short-term deposits with original maturities of three months or less that are readily convertible to a known amount of cash and which are subject to insignificant risk of changes in value. The accrued salaries suspense account (see note 7.1.2 'Restricted cash and cash equivalents') consists of amounts paid into a Treasury special purpose account to meet the additional cash outflow for employee salary payments in reporting period with 27 pays instead of the normal 26. No interest is received on this account. < 174 > Contents About us Significant issues Report on operations Agency performance Operational disclosures ⚫Key performance indicators Financial disclosures and compliance • Appendix

View entire presentation